Effect of bromocriptine in patients with apomorphine-responsive erectile impotence: an open study.
An open pilot study was undertaken to investigate the therapeutic effect of the dopaminergic agent, bromocriptine (BC), in impotent patients who developed an erectile response to the dopamine receptor agonist, apomorphine. Eight out of 17 patients reported improvement in ability to obtain an erection; five of these 8 subjects were able to achieve penetration. The optimum dose of BC was 2.5 - 11.25 mg/day. A double-blind placebo-controlled study is merited.
Lal
S
S
Department of Psychiatry, Montreal General Hospital, Quebec, Canada.
Kiely
M E
ME
Thavundayil
J X
JX
Stewart
J D
JD
Assalian
P
P
Ackman
C F
CF
D000328:Adult; D001058:Apomorphine / Q000627:therapeutic use*; D001971:Bromocriptine / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged
D001971:Bromocriptine; D001058:Apomorphine